Zevra Therapeutics (ZVRA) EBT (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of EBT data on file, last reported at $44.8 million in Q1 2026.

• Quarterly EBT rose 2437.19% year-over-year to $44.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.4 million (up 277.0% YoY) and the FY2025 annual result came in at $86.7 million, up 196.16% from the prior year.
• EBT improved to $44.8 million in Q1 2026, from $12.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $76.9 million in Q2 2025 to a low of -$33.2 million in Q3 2024.
• A 5-year average of -$1.5 million and a median of -$5.7 million in 2022 frame the typical range for EBT.
• Annual changes were most pronounced in 2024 — EBT tumbled 650.09% — and 2026, when it soared 2437.19%.
• Tracing ZVRA's EBT over 5 years: stood at -$3.0 million in 2022, then plunged by 561.74% to -$19.9 million in 2023, then fell by 2.39% to -$20.4 million in 2024, then soared by 162.19% to $12.7 million in 2025, then soared by 253.73% to $44.8 million in 2026.
• The last three EBT figures came in at $44.8 million (Q1 2026), $12.7 million (Q4 2025), and -$977000.0 (Q3 2025), per Business Quant data.